D.A. Davidson & CO. Has $8.24 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

D.A. Davidson & CO. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,174 shares of the medical instruments supplier’s stock after buying an additional 691 shares during the quarter. D.A. Davidson & CO.’s holdings in Becton, Dickinson and Company were worth $8,240,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. WR Wealth Planners LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Clear Creek Financial Management LLC lifted its stake in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC boosted its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division increased its stake in Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares in the last quarter. Finally, Tompkins Financial Corp increased its position in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on BDX. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $224.20 on Wednesday. The firm has a market cap of $64.80 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 1.67 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The stock has a 50-day moving average price of $234.83 and a 200-day moving average price of $234.40. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.42 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.86%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.